The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Cigna Ends Preauthorization Requirement to Treat Opioid Addiction

Cigna Ends Preauthorization Requirement to Treat Opioid Addiction

October 22, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—Health insurer Cigna Corp. has discontinued its policy of requiring doctors to seek authorization before treating opioid addicts, as part of a fight against an epidemic of opioid abuse, New York Attorney General Eric Schneiderman said on Friday.

You Might Also Like
  • U.S. to Promote Use of Opioid Alternatives to Treat Addiction
  • U.S. FDA Approves First-Ever Implant to Treat Opioid Addiction
  • U.S. Panel Backs Approval of Abuse-Resistant Opioid Painkiller

The policy change will apply nationally, says Schneiderman, who has been pushing for easier access to treatments for the estimated 2.2 million Americans who need treatment for abuse of heroin or prescription painkillers.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Preauthorization requirements can lead to significant delays in treatment, and other health insurers are encouraged to follow Cigna’s lead, Schneiderman says in a statement.1

Lawmakers around the country are seeking ways to stem the epidemic, which kills 78 Americans every day.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Fewer than half of addicts are receiving help, according to the U.S. Centers for Human and Health Services.

Cigna previously required doctors to submit a prior-approval form for medication-assisted treatment requests, answering questions about the patient’s current treatment and medical history.

This change was made to minimize the risk of illicit redistribution of drugs, but opponents argue that this approach has left the healthcare system unable to cope with the rising number of addicts.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. New York State Office of the Attorney General. News release: A.G. Schneiderman Announces National Settlement With Cigna To Discontinue Pre-Authorization For Opioid Addiction Treatment Drugs. 2016 Oct 21.

Filed Under: Legal Tagged With: Cigna Corp., Drugs, Health Insurance, Healthcare, Opioid abuse, Opioids

You Might Also Like:
  • U.S. to Promote Use of Opioid Alternatives to Treat Addiction
  • U.S. FDA Approves First-Ever Implant to Treat Opioid Addiction
  • U.S. Panel Backs Approval of Abuse-Resistant Opioid Painkiller
  • Cigna to End OxyContin Painkiller Coverage, Signs Contract for Alternative

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)